{"id":"iv-novolin-r-human-insulin","safety":{"commonSideEffects":[{"rate":"variable, dose-dependent","effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Human insulin mimics the body's natural insulin hormone by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into these cells and promoting glycogen synthesis while inhibiting gluconeogenesis. When administered intravenously, it provides rapid glucose control suitable for acute hyperglycemia management and perioperative settings. Novolin R is a recombinant human insulin produced through biotechnology.","oneSentence":"Novolin R is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:38.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"},{"name":"Acute hyperglycemia and diabetic ketoacidosis (IV formulation)"}]},"trialDetails":[{"nctId":"NCT07167693","phase":"PHASE1, PHASE2","title":"Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes","status":"RECRUITING","sponsor":"David K Carroll","startDate":"2025-12-19","conditions":"Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes","enrollment":60},{"nctId":"NCT06036823","phase":"PHASE4","title":"5 Versus 10 Units of Insulin in Hyperkalemia Management","status":"COMPLETED","sponsor":"Oman Medical Speciality Board","startDate":"2023-10-01","conditions":"Hyperkalemia, Potassium Imbalance, Electrolyte Imbalance","enrollment":384},{"nctId":"NCT01528189","phase":"NA","title":"Effect of High Dose Insulin on Infectious Complications Following Major Surgery","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2018-10-05","conditions":"Surgical Site Infection After Major Surgery","enrollment":460},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT02102243","phase":"PHASE4","title":"Neural Mechanism of Aldosterone-induced Insulin Resistance","status":"WITHDRAWN","sponsor":"Wanpen Vongpatanasin","startDate":"2010-11","conditions":"Hypertension","enrollment":""},{"nctId":"NCT03526536","phase":"PHASE4","title":"Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD","status":"TERMINATED","sponsor":"State University of New York - Downstate Medical Center","startDate":"2018-05-01","conditions":"End-Stage Renal Disease, Diabetes Mellitus","enrollment":40},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT00394524","phase":"NA","title":"Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-06","conditions":"Diabetes or With New Hyperglycemia","enrollment":160},{"nctId":"NCT02443402","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Coronary Artery Disease","enrollment":68},{"nctId":"NCT02451917","phase":"PHASE4","title":"Glargine Versus NPH in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus, Chronic Kidney Disease","enrollment":34},{"nctId":"NCT02982551","phase":"EARLY_PHASE1","title":"Insulin Modulation of fMRI Connectivity in Healthy Adults","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2016-01-01","conditions":"Healthy Volunteers","enrollment":""},{"nctId":"NCT00967837","phase":"PHASE2, PHASE3","title":"Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics","status":"TERMINATED","sponsor":"Florida Atlantic University","startDate":"2006-01","conditions":"Wound Healing, Diabetes","enrollment":152},{"nctId":"NCT00719108","phase":"PHASE1","title":"Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2008-07","conditions":"Diabetes","enrollment":42},{"nctId":"NCT01151176","phase":"PHASE4","title":"Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome","status":"SUSPENDED","sponsor":"Universidade Positivo","startDate":"2012-08","conditions":"Acute Coronary Syndrome","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ"],"phase":"marketed","status":"active","brandName":"IV Novolin R human insulin","genericName":"IV Novolin R human insulin","companyName":"State University of New York - Downstate Medical Center","companyId":"state-university-of-new-york-downstate-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Novolin R is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus, Acute hyperglycemia and diabetic ketoacidosis (IV formulation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}